Image may be NSFW.
Clik here to view.
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
| Yescarta is the second gene therapy product approval in the U.S. |
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL). Continue reading.
/////////FDA, CAR-T cell therapy, large B-cell lymphoma, fda 2017, Yescarta, axicabtagene ciloleucel,
Filed under: FDA 2017 Tagged: axicabtagene ciloleucel, CAR-T cell therapy, fda, FDA 2017, large B-cell lymphoma, Yescarta Image may be NSFW.
Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
